Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients

Leukemia

Volumn 11, Issue 9, 1997, Pages 1435-1441

  Broughton, C M ^a   Spiller, D G ^b   Pender, N ^a   Komorovskaya, M ^a,c   Grzybowski, J ^a   Giles, R V ^b   Tidd, D M ^b   Clark, R E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Hospital No 9   (Belarus)

Author keywords

Antisense gene therapy; Chronic myeloid leukaemia; Streptolysin O

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CD34 ANTIGEN; FLUORESCEIN; MESSENGER RNA; PROPIDIUM IODIDE; STREPTOLYSIN O;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL;

EID: 0030850489     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400774     Document Type: Article

References (16)

1. Carella AM, Gaozza E, Raffo MR, Carlier P, Frassoni F, Valbonesi M, Lercari G, Sessarego M, Defferrari R, Guerrasio A, Saglio G, Canepa L, Gaetani GF, Occhini D. Therapy of acute phase chronic myelogenous leukaemia with intensive chemotherapy, blood cell autotransplant and cyclospprine A. Leukemia 1991; 5: 517-521.
2. Chalmers EA, Franklin IM, Kelsey SM, Nevvland AC, Clark RE, Sproul AM, Crotty G, McCann SR, Fielding A, Goldstone AH, Hepplestone A, Watson W, Sharp RA, Tansey P. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilisation of Philadelphia negative peripheral blood stem cells. Br J Haematol 1997; 96: 627-634.
3. Clark RE. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Leuk Lymphoma 1995; 19: 189-195.
4. Tonkinson JL, Stein CA. Patterns of intracellular compartmentalisation, trafficking and acidification of 5'-fluorescein labelled phosphodiester and phosphorothioate oligodeoxyribonucleotides in HL60 cells. Nucleic Acids Res 1994; 22: 4268-4275.
5. Moller P, Johnsen HE, Dahl O. Stability and cellular uptake of phosphorothioate oligodeoxyribonucleotides (PS-ODNs) in human stem cells. Bone Marrow Transplant 1995; 15 (Suppl. 2): S107.
6. Barry ELR, Gesek FA, Friedman PA. Introduction of antisense oligodeoxynucleotides into cells by permeabilisation with Streptolysin-O. Biotechniques 1993; 15: 1016-1020.
7. Spiller DG, Tidd DM. Nuclear delivery of antisense oligodeoxyribonucleotides through reversible permeabilisation of human leukaemia cells with streptolysin O. Antisense Res Devel 1995; 5: 13-21.
8. Giles RV, Spiller DG, Green JA, Clark RE, Tidd DM. Optimisation of antisense oligodeoxynucleotide structure for targeting BCR-ABL mRNA. Blood 1995; 86: 744-754.
9. Spiller DG, Tidd DM. The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. AntiCancer Drug Design 1992; 7: 115-119.
10. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukaemia cell lines. Leukemia 1994; 8: 2156-2162.
11. Gao WY, Storm C, Egan W, Cheng YC. Cellular pharmacology of phosphorthioate homooligodeoxynucleotides in human cells. Mol Pharm 1993; 43: 45-50.
12. Boutorin AS, Gus'kova LV, Ivanova EM, Kobetz ND, Zarytova VF, Ryte AS, Yurchenko LV, Vlassov W. Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazium residues at their 3′-terminus and their interaction with DNA within mammalian cells. FEBS Lett 1989; 254: 129-132.
13. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 1991; 10: 1111-1118.
14. Clark RE, Grzybowski J, Spiller DG, Tidd DM. Effect of conjugates on antisense oligonucleotide uptake into chronic myeloid leukaemia cells. Blood 1996; 88 (Suppl. 1): 297b.
15. de Fabritiis P, Montefusco E, Avvisati G, Sala R, Mancini M, Lisci A, Geiser T, Calabretta B, Mandelli F. Bone Marrow (BM) purging with BCR-ABL antisense oligonucleotides (ODNs) and autograft for patients with chronic myelogenous leukaemia in advanced phase. Bone Marrow Transplant 1995; 15 (Suppl. 2): 5107.
16. Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A, Ratajczak MZ. Oligodeoxynucleotide therapeutics for human myelogenous leukaemia: interim results. Blood 1996; 88 (Suppl. 1): 270a.